MedTrace Logo

Smoking Treatment of Prisoners

NCT00110630 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.

Conditions

  • Tobacco Use Cessation
  • Tobacco Use Disorder

Interventions

BEHAVIORAL

10-week smoking cessation group therapy combined with NicoDerm CQ

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Karen Cropsey, Ph.D. · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00110630 on ClinicalTrials.gov